Rocket


Overview
Financials
News + Filings
Key Docs
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Omthera Pharmaceuticals, Inc. (OMTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2013 8-K Quarterly results
07/16/2013 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Omthera Stockholders Approve Acquisition by AstraZeneca"
05/28/2013 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among Omthera Pharmaceuticals, Inc., Zeneca, Inc. and KAFA Acquisition Corp",
"Form of Contingent Value Rights Agreement, by and between Zeneca, Inc. and the Rights Agent",
"Stockholder Voting Agreement, by and between Zeneca, Inc. and Gerald L. Wisler",
"Stockholder Voting Agreement, by and between Zeneca, Inc. and Michael H. Davidson",
"Stockholder Voting Agreement, by and among Zeneca, Inc., New Enterprise Associates 13, L.P., and NEA Ventures 2001, Limited Partnership",
"Stockholder Voting Agreement, by and between Zeneca, Inc. and Sofinnova Capital VI FCPR"
05/28/2013 8-K Quarterly results
Docs: "Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results",
"AstraZeneca to Acquire Omthera Pharmaceuticals Including NDA-Ready Novel Dyslipidemia Treatment to Complement Cardiovascular Portfolio AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. Omthera's investigational product, EpanovaTM, for the potential treatment of patients with very high triglycerides, is a novel omega-3 free fatty acid composition that has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid significantly in the blood. In studies to date, it has been shown to reduce triglyceride levels ..."
04/26/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy